In Alzheimer’s disease, for example, the accumulation of neurotoxic KP metabolites can exacerbate amyloid-beta and tau pathologies, driving disease progression (Guillemin & Brew 2002; Onyango et al. 2021). This evidence concerns the gene MAPT and Alzheimer disease.